Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.

Also called NCT01788046

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 515 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01788046
  • EudraCT 2012-002806-31
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01788046. Randomized; triple masking; primary purpose treatment. Start 2013-03-12 (actual); primary completion 2014-04-14 (actual). Results posted on 2017-03-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
Condition
Hyperparathyroidism, Secondary
Intervention (Drug)
Etelcalcetide
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01788046
Content hash
299c1e54584fce49353be22e6f9648cfd10a42f7a9b2be1e699a6a827c8326f2